BioShai is validating and standardizing the PDx assay in a multi-center clinical trial, PDX001, in Israel and Italy.
Following, the PDx assay will be transferred and qualified in service labs that can offer PDx to prescribing physicians.
PDx assays will be ready for sales in 2017 after the completion of our scheduled validation trial.
Dr. Jennifer S. Yarden, PhD, CEO Jennifer Yarden has over 15 years’ experience in the scientific, medical and in vitro diagnostic sectors. Jennifer specializes in the clinical development and commercialization of diagnostic and prognostic kits. As the Director of Clinical Development at Glycominds Ltd., Jennifer played a major role in the design, development, marketing and commercialization of the company’s diagnostic assays and kits for the diagnosis and prognosis of Multiple Sclerosis and Crohn’s disease. Prior to Glycominds Jennifer was a Senior Clinical Research Associate and Scientific Writer at Deep Breeze Ltd., a company dealing in the diagnosis and prognosis of lung diseases. Jennifer holds a B.Sc. in Biotechnology with honors from Tel Chai Academic College, Israel. Jennifer’s Ph.D. is in Medical Science from KU Leuven, Belgium, her thesis subject was genetic biomarkers for the prognosis and diagnosis of respiratory diseases. Jennifer is also the co-founder and CEO of Curewize Health, which is developing a predictive test for acute lymphoblastic leukemia.
Dr. Nir Dotan, PhD, CTO Nir was the cofounder, Vice President and CTO of Glycominds Ltd. and has over 15 years' experience in the development and commercialization of in vitro diagnostic assays and kits. Nir created and developed a glycan micro array technology for profiling glycan protein interactions. Nir successfully discovered, validated and translated to clinical practice the IBDX blood test as an aid in diagnosis and risk stratification of Crohn's disease patients. Nir also developed the gMS blood test as an aid in diagnosis and risk stratification of Multiple sclerosis patients. Nir’s proven experience in clinical and technological development and commercialization of biomarkers from bench to the market is a great asset to BioShai. Nir has a PhD in Biotechnology from the Tel Aviv University and is also the CTO of Curewize.
Prof. Martin Rabey, MD, CMO Martin obtained board certification in neurology in 1973. He worked at the Tel Aviv Medical Center (Ichilov Hospital) till 1995 when he was elected to chair the Department of Neurology at Assaf Harofe Medical Center. He was the Chairman of the Cathedra of Neurology at Tel Aviv University since 2000 till 2003. He has published more than 200 original articles in Neurochemistry and Neuropharmacology. He authored chapters in several books as an international expert in Parkinson’s and Alzheimer Disease. He worked several years in the USA - with the late Menek Goldstein in the University Medical Center of New York; Franz Hefti in the Parkinson National Foundation in Miami; with R Burns at the Nerve Disorder Research Laboratory in Nashville, among others. He was the active Chairman of the Scientific Advisory board for the Israeli Parkinson Association from 2000 till 2007. In 2003 he developed with some colleagues from Europe the SPES, (Simple Parkinson Evaluation Scale) a very practical scoring scale for the evaluation of Parkinsonian patients that is frequently used in Europe.